CliffBio
small molecule

FINACEA

AZELAIC ACID

Loss of exclusivity—loss of exclusivity
CompanyLEO PHARMA AS

Drug detail

Brand nameFINACEA
Active ingredientAZELAIC ACID
Strength15%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2002
Marketing statusRX

More from LEO PHARMA AS

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FINACEA patent cliff — loss of exclusivity — | CliffBio